» Articles » PMID: 37248346

Bone Scan Index (BSI) Scoring by Using Bone Scintigraphy and Circulating Tumor Cells (CTCs): Predictive Factors for Enzalutamide Effectiveness in Patients with Castration-resistant Prostate Cancer and Bone Metastases

Abstract

Reports of Bone Scan Index (BSI) calculations as imaging biomarkers to predict survival in patients with metastatic castration-resistant prostate cancer (mCRPC) have been mainly from retrospective studies. To evaluate the effectiveness of enzalutamide (ENZ) in Japanese patients with mCRPC and bone metastases using BSI (bone scintigraphy) and circulating tumor cell (CTC) analysis. Prospective, single-arm study at Juntendo University affiliated hospitals, Japan. Patients were administered 160 mg ENZ daily, with 3 monthly assessments: BSI, prostate specific antigen (PSA), CTC and androgen receptor splicing variant-7 (AR-V7) status. Primary endpoint: BSI-decreasing rate after ENZ treatment. Secondary endpoints: PSA-decreasing rate and progression free survival (PFS). Statistical analyses included the Wilcoxon t-test, Cox proportional hazard regression analysis, and log-rank test. Median observation period: 17.9 months, and median PFS: 13.8 (2.0-43.9) months (n = 90 patients). A decrease in BSI compared to baseline as best BSI change on ENZ treatment was evident in 69% patients at the end of the observation period (29% patients showed a complete response, BSI 0.00). At 3 months 67% patients showed a ≥ 50% PSA reduction, and 70% after ENZ treatment. PSA decline (3 months) significantly associated with a prolonged median PFS: 18.0 (estimated) versus 6.4 months (HR 2.977 [95% CI 1.53-5.78], p = 0.001). Best BSI decline response significantly associated with a prolonged PFS: 18.1(estimated) versus 7.8 months (HR 2.045 [95% CI: 1.07-3.90], p = 0.029). CTC negative status (n = 20) significantly associated with a prolonged PFS: 13.4 [estimated] vs 8.6 months (HR 2.366, 95% CI 0.97-5.71, p = 0.041). CTC positive/AR-V7 positive status significantly associated with a shorter PFS: 5.9 months (HR 8.56, 95% CI 2.40-30.43, p = 0.0087). -reduction (3 months) and BSI-reduction (on ENZ treatment) were significant response biomarkers, and a negative CTC status was a predictive factor for ENZ efficacy in patients with mCRPC.

Citing Articles

A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells.

Bahmaie N, Ozensoy Guler O, Simsek E J Liq Biopsy. 2025; 6:100169.

PMID: 40027303 PMC: 11863822. DOI: 10.1016/j.jlb.2024.100169.


The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide.

Nakamura S, Nagata M, Nagaya N, Ashizawa T, Hirano H, Lu Y Cancers (Basel). 2024; 16(4).

PMID: 38398163 PMC: 10886552. DOI: 10.3390/cancers16040772.


Recent advances and future perspectives in the therapeutics of prostate cancer.

Varaprasad G, Gupta V, Prasad K, Kim E, Tej M, Mohanty P Exp Hematol Oncol. 2023; 12(1):80.

PMID: 37740236 PMC: 10517568. DOI: 10.1186/s40164-023-00444-9.

References
1.
Saad F, Gleason D, Murray R, Tchekmedyian S, Venner P, Lacombe L . A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19):1458-68. DOI: 10.1093/jnci/94.19.1458. View

2.
Smith M, Saad F, Coleman R, Shore N, Fizazi K, Tombal B . Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2011; 379(9810):39-46. PMC: 3671878. DOI: 10.1016/S0140-6736(11)61226-9. View

3.
Armstrong A, Lin P, Tombal B, Saad F, Higano C, Joshua A . Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol. 2020; 78(3):347-357. DOI: 10.1016/j.eururo.2020.04.061. View

4.
Beer T, Armstrong A, Rathkopf D, Loriot Y, Sternberg C, Higano C . Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371(5):424-33. PMC: 4418931. DOI: 10.1056/NEJMoa1405095. View

5.
Marrugo-Ramirez J, Mir M, Samitier J . Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy. Int J Mol Sci. 2018; 19(10). PMC: 6213360. DOI: 10.3390/ijms19102877. View